In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H2S to treat diabetic wounds

Lin, Wei-Chih; Huang, Chieh‐Cheng; Lin, Shaw‐Tao; Li, Meng-Ju; Chang, Yen; Lin, Yu‐Jung; Wan, Wei‐Lin; Shih, Po‐Chien; Sung, Hsing‐Wen

doi:10.1016/j.biomaterials.2017.08.023

Cited by 63 publications

(56 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, another H 2 S-releasing depot formulation (termed "NaHS@MPs") has been produced for the therapy of wound healing (Lin et al, 2017). The formulation involves a microparticle system comprising of hydrophobic phase-change materials (1-tetradecanol and paraffin wax).…”

Section: H 2 S-donating Polymers and Special Pharmaceutical Formentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors

2017

View full text Add to dashboard Cite

Over the last decade, hydrogen sulfide (HS) has emerged as an important endogenous gasotransmitter in mammalian cells and tissues. Similar to the previously characterized gasotransmitters nitric oxide and carbon monoxide, HS is produced by various enzymatic reactions and regulates a host of physiologic and pathophysiological processes in various cells and tissues. HS levels are decreased in a number of conditions (e.g., diabetes mellitus, ischemia, and aging) and are increased in other states (e.g., inflammation, critical illness, and cancer). Over the last decades, multiple approaches have been identified for the therapeutic exploitation of HS, either based on HS donation or inhibition of HS biosynthesis. HS donation can be achieved through the inhalation of HS gas and/or the parenteral or enteral administration of so-called fast-releasing HS donors (salts of HS such as NaHS and NaS) or slow-releasing HS donors (GYY4137 being the prototypical compound used in hundreds of studies in vitro and in vivo). Recent work also identifies various donors with regulated HS release profiles, including oxidant-triggered donors, pH-dependent donors, esterase-activated donors, and organelle-targeted (e.g., mitochondrial) compounds. There are also approaches where existing, clinically approved drugs of various classes (e.g., nonsteroidal anti-inflammatories) are coupled with HS-donating groups (the most advanced compound in clinical trials is ATB-346, an HS-donating derivative of the non-steroidal anti-inflammatory compound naproxen). For pharmacological inhibition of HS synthesis, there are now several small molecule compounds targeting each of the three HS-producing enzymes cystathionine--synthase (CBS), cystathionine--lyase, and 3-mercaptopyruvate sulfurtransferase. Although many of these compounds have their limitations (potency, selectivity), these molecules, especially in combination with genetic approaches, can be instrumental for the delineation of the biologic processes involving endogenous HS production. Moreover, some of these compounds (e.g., cell-permeable prodrugs of the CBS inhibitor aminooxyacetate, or benserazide, a potentially repurposable CBS inhibitor) may serve as starting points for future clinical translation. The present article overviews the currently known HS donors and HS biosynthesis inhibitors, delineates their mode of action, and offers examples for their biologic effects and potential therapeutic utility.

show abstract

Section: H 2 S-donating Polymers and Special Pharmaceutical Formentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors

2017

View full text Add to dashboard Cite

show abstract

“…Lin et al used emulsion technique to prepare NaHS particles (NaHS@MPs), which could be used as in situ depot for continuous release of exogenous H 2 S under physiological conditions. 197 The sustained release of H 2 S from NaHS@MPs promotes several cell behaviors, including epidermal/endothelial cell proliferation and migration, as well as angiogenesis, by extending the activation of cellular ERK1/2 and p38, [181,[192][193][194] Sodium percarbonate PCL nanofibers scaffolds Continuously generating oxygen for up to 10 days [190] Sodium hydrosulfide NaHS@MPs NaHS@MPs sustained release of exogen-ous H2S under physiological conditions [197] Nitric oxide DNICs Continuous release of nitric oxide [201] submit your manuscript | www.dovepress.com…”

Section: Hydrogen Sulfide Containing Nanocarriersmentioning

confidence: 99%

<p>Potential Applications of Nanomaterials and Technology for Diabetic Wound Healing</p>

Bai¹,

Han²,

Dong³

et al. 2020

IJN

147

114

View full text Add to dashboard Cite

Diabetic wound shows delayed and incomplete healing processes, which in turn exposes patients to an environment with a high risk of infection. This article has summarized current developments of nanoparticles/hydrogels and nanotechnology used for promoting the wound healing process in either diabetic animal models or patients with diabetes mellitus. These nanoparticles/hydrogels promote diabetic wound healing by loading bioactive molecules (such as growth factors, genes, proteins/peptides, stem cells/exosomes, etc.) and nonbioactive substances (metal ions, oxygen, nitric oxide, etc.). Among them, smart hydrogels (a very promising method for loading many types of bioactive components) are currently favored by researchers. In addition, nanoparticles/hydrogels can be combined with some technology (including PTT, LBL self-assembly technique and 3D-printing technology) to treat diabetic wound repair. By reviewing the recent literatures, we also proposed new strategies for improving multifunctional treatment of diabetic wounds in the future.

show abstract

“…More recently, Lin et al (2017) have produced an H 2 S-releasing depot formulation (termed "NaHS@MPs") for treatment of diabetic wounds.…”

Section: Dermal Wound Healing and Angiogenesismentioning

confidence: 99%

Hydrogen sulfide and dermatological diseases

Coavoy-Sánchez

Costa

Muscará

2019

British J Pharmacology

View full text Add to dashboard Cite

Skin diseases constitute a major health problem affecting a high proportion of the population every day and have different aetiologies that include inflammation, infections, and tumours. Hydrogen sulfide (H2S) is a gaseous signalling molecule recognized as a gasotransmitter together with NO and carbon monoxide. Under physiological conditions, H2S is produced in the skin by enzymic pathways and plays a physiological role in a variety of functions, such as vasodilatation, cell proliferation, apoptosis, and inflammation. Alterations of H2S production are implicated in a variety of dermatological diseases, such as psoriasis, melanoma, and other dermatoses. On the other hand, H2S‐releasing‐based therapies based on H2S donor compounds are being developed to treat some of these situations. In this review, we provide an up‐to‐date overview of the role of H2S in the normal skin and its clinical and pathological significance, as well as the therapeutic potential of different H2S donors for treatment of skin diseases. Linked Articles This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc

show abstract

In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H2S to treat diabetic wounds

Cited by 63 publications

References 26 publications

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors

<p>Potential Applications of Nanomaterials and Technology for Diabetic Wound Healing</p>

Hydrogen sulfide and dermatological diseases

Contact Info

Product

Resources

About

In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H2S to treat diabetic wounds

Cited by 63 publications

References 26 publications

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors

<p>Potential Applications of Nanomaterials and Technology for Diabetic Wound Healing</p>

Hydrogen sulfide and dermatological diseases

Contact Info

Product

Resources

About

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H₂S Levels: H₂S Donors and H₂S Biosynthesis Inhibitors